An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 112 participants.
Also called NCT03775421
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 112 participants
- Sponsor
- Registry
-
NCT03775421 -
2018-002821-45
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, China, Czechia, Denmark, France, New Zealand, Poland, Taiwan, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT03775421. Allocation not applicable; no masking; primary purpose treatment. Start 2019-04-11 (actual); primary completion 2022-01-18 (actual). Results posted on 2023-03-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.
- Acronym
- RUBATO OL
- Condition
- Congenital Heart Disease With Fontan Circulation
- Intervention (Drug)
- macitentan 10 mg
- Lead sponsor
- Actelion
- Collaborator
- Covance
- Collaborator
- Henry Ford Health System
- Collaborator
- Almac Clinical Technologies
- Collaborator
- ActiGraph LLC
- Collaborator
- Medidata Solutions
Record details
- Record id
cardio:ct-nct03775421- Content hash
60dfe5d75f35d2b00291df015a73df34d3180875193301e336f01ef927fc3999